Table 1.
Clinicopathological details of patients included in the study.
| Clinicopathological Variables | PCa (n = 65) | BPH (n = 58) |
|---|---|---|
| median age, years (range) | 65 (40–92) | 63 (47–78) |
| pre-biopsy PSA median, µg/L (n; 25–75 percentile) | 7.10 (64; 5.53–10.67) | 7.82 (58; 5.48–10.14) |
| pre-biopsy PSA levels, n (%) | ||
| ≤10 µg/L | 46 (70.8%) | 42 (72.4%) |
| >10 µg/L | 18 (27.7%) | 16 (27.6%) |
| unknown | 1 (1.5%) | 0 (0%) |
| GS, n (%) | ||
| 6 | 19 (29.2%) | n.a. |
| 7 | 40 (61.5%) | n.a. |
| 8 | 4 (6.2%) | n.a. |
| 9 | 2 (3.1%) | n.a. |
| WHO 2016/ISUP grade | ||
| 1 (GS 3 + 3 = 6) | 19 (29.2%) | n.a. |
| 2 (GS 3 + 4 = 7) | 30 (46.1%) | n.a. |
| 3 (GS 4 + 3 = 7) | 10 (15.4%) | n.a. |
| 4 (GS 4 + 4, 3 + 5 or 5+3 = 8) | 4 (6.2%) | n.a. |
| 5 (GS 9 or 10) | 2 (3.1%) | n.a. |
Abbreviations: PCa, prostate cancer; BPH, benign prostatic hyperplasia; WHO, World Health Organization; ISUP, International Society of Urological Pathology; n.a., not applicable.